A provider-focused update on the Acetazolamide shortage in 2026, covering supply status, prescribing implications, alternatives, and patient access tools.
Acetazolamide remains a workhorse medication across multiple specialties — from ophthalmology and neurology to pulmonology and emergency medicine. Following the injectable shortage that began in late 2022, many providers are still fielding questions from patients about availability. This briefing provides a concise, up-to-date overview of where things stand in 2026.
In October 2022, the American Society of Health-System Pharmacists (ASHP) reported a shortage of Acetazolamide Sodium injection (500 mg lyophilized powder for reconstitution). The shortage affected hospital-based protocols for acute glaucoma management, perioperative IOP reduction, and metabolic alkalosis treatment in ICU settings.
By February 2024, ASHP updated the shortage bulletin to indicate that all marketed presentations of the injectable form were available. The shortage was attributed to manufacturing and supply chain disruptions, not demand surges.
Throughout this period, oral formulations — including the 125 mg and 250 mg immediate-release tablets and the 500 mg extended-release capsule (formerly Diamox Sequels) — were not subject to a formal shortage. However, isolated supply disruptions at the pharmacy level have persisted due to stocking practices and wholesaler allocation.
The shortage had several downstream effects on prescribing patterns that providers should be aware of:
During the injectable shortage, many inpatient protocols shifted from IV Acetazolamide to oral dosing. While oral Acetazolamide is well-absorbed and effective for most indications, the IV form provides faster onset and is preferred in acute settings (e.g., acute angle-closure glaucoma, rapid IOP reduction pre-surgery). Providers should verify that their institutional formularies have been updated now that the injectable is back in supply.
Some institutions implemented therapeutic substitution protocols during the shortage. Common substitutions included:
If your institution still has substitution protocols in place, consider reviewing and updating them based on current availability.
As of early 2026, Acetazolamide supply is generally stable:
That said, retail pharmacy availability can be inconsistent. Acetazolamide is a niche medication that many community pharmacies don't stock in depth. Patients may encounter stock-outs at their usual pharmacy, particularly in areas without high prescribing volume.
Cost can be a significant barrier for patients, especially those without insurance:
There are no manufacturer savings programs or copay cards for Acetazolamide, as it's a long-established generic with no active brand promotion. For uninsured or underinsured patients, NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain directories of assistance programs. Discount cards remain the most practical option for immediate cost relief.
For detailed patient-facing cost information, see how to save money on Acetazolamide.
Several resources can help streamline the process when patients can't find Acetazolamide:
Medfinder offers a provider-facing tool that helps locate pharmacies with medications in stock. You can direct patients to check availability at medfinder.com/providers or integrate this into your practice workflow. For a practical implementation guide, see how to help your patients find Acetazolamide in stock.
The ASHP Drug Shortage Resource Center (ashp.org/drug-shortages) provides real-time updates on current and resolved shortages. The Acetazolamide injection shortage bulletin remains available for reference.
For a patient-friendly summary of alternatives that you can share during conversations about treatment changes, see alternatives to Acetazolamide.
The Acetazolamide supply outlook is positive. Key factors working in the medication's favor:
The primary risk remains distribution-level gaps — situations where a pharmacy doesn't stock the medication or a regional wholesaler is temporarily out. These are best addressed through patient education and pharmacy-finding tools rather than changes in prescribing practice.
If patients report cost barriers, consider these approaches:
For a provider-specific guide on helping patients with costs, see how to help patients save money on Acetazolamide.
The formal Acetazolamide shortage has been resolved, but the practical reality is that patients may still encounter difficulty filling their prescriptions at specific pharmacies. As a prescriber, the most impactful things you can do are: stay aware of current availability, be prepared to discuss alternatives when needed, and point patients toward tools like Medfinder that can help them locate their medication without unnecessary delay.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
